
Clinical TrialNov 17, 2026, 06:09 AM
NeOnc Technologies: NEO100 Phase 2a Study Meets Primary Endpoint
AI Summary
NeOnc Technologies Holdings, Inc. announced positive results from its NEO100 Phase 2a study in recurrent IDH1-mutant grade III-IV glioma. The study met its primary endpoint with a 48.9% Progression-Free Survival at 6 months (PFS-6), significantly outperforming the 20% benchmark. Median Overall Survival (OS) at recurrence was 26.09 months, a substantial improvement over the 6-9 month historical benchmark. The company also provided an update on its NEO212 program, with Phase 1 dose escalation completed and preclinical data suggesting enhanced brain delivery and potential to overcome temozolomide resistance.
Key Highlights
- NEO100 Phase 2a study showed 48.9% PFS-6, meeting primary endpoint vs. 20% benchmark.
- Median Overall Survival (OS) for NEO100 at recurrence was 26.09 months, significantly exceeding the 6-9 month benchmark.
- Objective Response Rate (ORR) for NEO100 was 12.5% (3/24 patients), with 66.7% disease control.
- NEO100 Phase 2a study reported 60.9% of patients alive at 12 months post-recurrence.
- NEO212 Phase 1 dose escalation study completed, assessing safety and tolerability.
- NEO212 preclinical data suggests enhanced brain delivery and potential to overcome TMZ resistance.
Price Impact
More from NTHI